Efficacy and Safety of Trastuzumab Combined with Pertuzumab for Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer: A Meta-Analysis Study of Randomized Control Trials

Table 1

Study characteristics and baseline characteristics of the included studies.

No	Author (year)	Age (tre/con)	Cases (female/male)		Intervention		Study type	Outcomes
			Treatment	Control	Treatment	Control
1	J.X. Tang, 2022	41.50 ± 8.45; 42.00 ± 8.50	30/0	30/0	Trastuzumab + pertuzumab + docetaxel	Trastuzumab + docetaxel	RCT	⑥⑦⑧
2	L. Chen, 2022	52.18 ± 14.97; 51.91 ± 14.32	42/0	42/0	Trastuzumab + pertuzumab	Trastuzumab	RCT	④⑤⑦⑩⑫
3	S.Y. MA, 2021	43.92 ± 21.77; 45.78 ± 20.86	23	23	Trastuzumab + pertuzumab + basic treatment	Trastuzumab + basic treatment	RCT	②④⑤⑧⑨
4	Swain, Sandra M, 2020	—	407/1	396/0	Trastuzumab + pertuzumab + docetaxel	Placebo + trastuzumab + docetaxel	RCT	②③④⑤⑥⑦⑧⑨
5	von Minckwitz, Gunter, 2017	51.7 ± 10.9; 51.4 ± 10.7	2397/3	2396/8	Trastuzumab + pertuzumab + docetaxel	Placebo + trastuzumab + docetaxel	RCT	②③⑪⑫⑬
6	Gianni, Luca, 2016	—	107/0	107/0	Trastuzumab + pertuzumab + docetaxel	Trastuzumab + docetaxel	RCT	①②③④⑤⑥⑦⑧⑩⑪⑫⑬
7	Fleeman, Nigel, 2015	—	402/0	406/0	Trastuzumab + pertuzumab + docetaxel	Placebo + trastuzumab + docetaxel	RCT	①⑩⑪⑫⑬
8	Swain, Sandra M, 2015	—	402/0	406/0	Trastuzumab + pertuzumab + docetaxel	Placebo + trastuzumab + docetaxel	RCT	①②③④⑤⑥⑦⑧⑨

RCT, randomized controlled trial; ①, progression-free survival, PFS; ②, diarrhea; ③, neutropenia; ④, nausea; ⑤, fatigue; ⑥, rash; ⑦, vomiting; ⑧, myalgia; ⑨, constipation; ⑩, any adverse event; ⑪, serious adverse event; ⑫, all cardiac disorders; ⑬, adverse event leading to death.